HLA Class I depleted hESC as a source of hypoimmunogenic cells for tissue engineering applications

Zaruhi Karabekian, Hao Ding, Gulnaz Stybayeva, Irina Ivanova, Narine Muselimyan, Amranul Haque, Ian Toma, Nikki G. Posnack, Alexander Revzin, David Leitenberg, Michael A. Laflamme, Narine Sarvazyan

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Background: Rapidly improving protocols for the derivation of autologous cells from stem cell sources is a welcome development. However, there are many circumstances when off-the-shelf universally immunocompatible cells may be needed. Embryonic stem cells (ESCs) provide a unique opportunity to modify the original source of differentiated cells to minimize their rejection by nonautologous hosts. Hypothesis: Immune rejection of nonautologous human embryonic stem cell (hESC) derivatives can be reduced by downregulating human leukocyte antigen (HLA) class I molecules, without affecting the ability of these cells to differentiate into specific lineages. Methods and Results: Beta-2-microglobulin (B2M) expression was decreased by lentiviral transduction using human anti-HLA class I light-chain B2M short hairpin RNA. mRNA levels of B2M were decreased by 90% in a RUES2-modified hESC line, as determined by quantitative real time-polymerase chain reaction analysis. The transduced cells were selected under puromycin pressure and maintained in an undifferentiated state. The latter was confirmed by Oct4 and Nanog expression, and by the formation of characteristic round-shaped colonies. B2M downregulation led to diminished HLA-I expression on the cell surface, as determined by flow cytometry. When used as target cells in a mixed lymphocyte reaction assay, transduced hESCs and their differentiated derivatives did not stimulate allogeneic T-cell proliferation. Using a cardiac differentiation protocol, transduced hESCs formed a confluent layer of cardiac myocytes and maintained a low level of B2M expression. Transduced hESCs were also successfully differentiated into a hepatic lineage, validating their capacity to differentiate into multiple lineages. Conclusions: HLA-I depletion does not preclude hESC differentiation into cardiac or hepatic lineages. This methodology can be used to engineer tissue from nonautologous hESC sources with improved immunocompatibility.

Original languageEnglish (US)
Pages (from-to)2559-2571
Number of pages13
JournalTissue Engineering - Part A
Volume21
Issue number19-20
DOIs
StatePublished - Oct 1 2015

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomaterials
  • Biomedical Engineering

Fingerprint Dive into the research topics of 'HLA Class I depleted hESC as a source of hypoimmunogenic cells for tissue engineering applications'. Together they form a unique fingerprint.

  • Cite this

    Karabekian, Z., Ding, H., Stybayeva, G., Ivanova, I., Muselimyan, N., Haque, A., Toma, I., Posnack, N. G., Revzin, A., Leitenberg, D., Laflamme, M. A., & Sarvazyan, N. (2015). HLA Class I depleted hESC as a source of hypoimmunogenic cells for tissue engineering applications. Tissue Engineering - Part A, 21(19-20), 2559-2571. https://doi.org/10.1089/ten.tea.2015.0105